Trial Profile
A prospective, multicenter phase II study to evaluate vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 12 Dec 2015 New trial record